Fibrin associated large B-cell lymphoma accidentally identified in a breast implant capsule: a molecular report of a rare entity
2024; Pacini Editore; Volume: 116; Issue: 4 Linguagem: Inglês
10.32074/1591-951x-944
ISSN1591-951X
AutoresCristian Scatena, Antonio Giuseppe Naccarato, Margherita Vannucchi, Maria Chiara Siciliano, Angelo Giovanni Bonadio, Livio Colizzi, Matteo Ghilli, Arianna Di Napoli, Giuseppe Nicolò Fanelli, Stefano Lazzi,
Tópico(s)Breast Cancer Treatment Studies
ResumoBreast implant-associated (BIA) lymphoma is a rare malignancy, typically originating from T-cells; however, few cases of diffuse large B-cell lymphoma (LBCL) have been recently described. These cases share major features: Epstein-Barr virus positivity and a favorable prognosis with surgical intervention alone, hinting at a potential link to fibrin-associated LBCL (FA-LBCL). This study presents the first case of BIA-FA-LBCL in Italy and one of the few assessed from a molecular standpoint so far. We identified two pathogenic mutations in DNMT3A and a variant of uncertain significance (VUS) in JAK2. These findings suggest that dysfunctional epigenetic mechanisms and constitutive activation of the JAK-STAT pathway may underpin BIA-FA-LBCL lymphomagenesis. Finally, we summarized all the previously reported cases in alignment with the updated WHO-HAEM5 classification, shedding further light on the nature of this new entity. This report highlights the rarity of BIA-FA-LBCL and underscores the importance of comprehensive capsule sampling and reporting to national databases for accurate characterization and management of these lymphomas. The study supports the classification of BIA-FA-LBCL within the spectrum of FA-LBCL, emphasizing the need for further research to elucidate its molecular underpinnings and improve clinical outcomes.
Referência(s)